L3VLUP
ProSign in

NBIX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NBIXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NBIX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterNBIXGILD
Q3 202015 holders, $2.6bn25 holders, $14.2bn
Q4 202012 holders, $2.6bn27 holders, $13.4bn
Q1 20216 holders, $2.3bn24 holders, $14.5bn
Q2 20219 holders, $1.5bn18 holders, $14.9bn
Q3 20218 holders, $1.5bn20 holders, $16.4bn
Q4 202114 holders, $1.3bn20 holders, $16.8bn
Q1 202215 holders, $1.4bn28 holders, $13.2bn
Q2 202211 holders, $1.3bn26 holders, $13.6bn
Q3 202214 holders, $1.0bn24 holders, $13.3bn
Q4 202215 holders, $1.2bn32 holders, $21.1bn
Q1 202317 holders, $860m27 holders, $21.8bn
Q2 202316 holders, $1.1bn24 holders, $20.7bn
Q3 202324 holders, $1.4bn24 holders, $20.0bn
Q4 202321 holders, $1.6bn22 holders, $21.5bn
Q1 202419 holders, $1.5bn30 holders, $20.3bn
Q2 202417 holders, $1.4bn28 holders, $18.5bn
Q3 202411 holders, $1.2bn29 holders, $24.2bn
Q4 202414 holders, $2.0bn28 holders, $25.9bn
Q1 202514 holders, $1.6bn33 holders, $32.0bn
Q2 202516 holders, $2.5bn27 holders, $30.9bn
Q3 202515 holders, $2.6bn23 holders, $29.4bn
Q4 202521 holders, $2.8bn25 holders, $34.3bn
Q1 202617 holders, $2.9bn25 holders, $38.5bn
Q2 202610 holders, $2.7bn26 holders, $34.2bn
NBIX

Neurocrine Biosciences Inc

Holders
14
Reported value
$2.0bn
Buyers
10
Sellers
4

Breadth +6 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
28
Reported value
$25.9bn
Buyers
14
Sellers
14

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NBIX (2)

Brevan Howard Capital Management LP, Soros Fund Management LLC

Only GILD (16)

Acadian Asset Management LLC, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Invesco Ltd, Marshall Wace LLP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →